64cu-dota-tlx592
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 4, 2021 (NCT04726033)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04726033 | Early Phase 1 (Phase 1) | Aug 4, 2021 | Telix |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telix | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1